Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

被引:5
|
作者
Gerlier, Laetitia [1 ]
Lamotte, Mark [1 ]
Mendes, Sofia Dos Santos [2 ]
Damm, Oliver [3 ]
Schwehm, Markus [4 ]
Eichner, Martin [5 ,6 ]
机构
[1] IMS Hlth Real World Evidence Solut, Davos Bldg,Vincilaan 7, B-1935 Zaventem, Belgium
[2] SA AstraZeneca NV, Uccle, Belgium
[3] Univ Bielefeld, Bielefeld, Germany
[4] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[5] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany
[6] Epimos GmbH, Dusslingen, Germany
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; ECONOMIC BURDEN; UNITED-STATES; EFFICACY; ENGLAND; GERMANY; FRANCE; TIME; METAANALYSIS;
D O I
10.1007/s40272-016-0180-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
引用
收藏
页码:303 / 318
页数:16
相关论文
共 50 条
  • [41] Influenza A virus shedding reduction observed at 12 weeks post-vaccination when newborn pigs are administered live-attenuated influenza virus vaccine
    Kaiser, Troy J.
    Smiley, Rex A.
    Fergen, Brian
    Eichmeyer, Marc
    Genzow, Marika
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2019, 13 (03) : 274 - 278
  • [42] CLINICAL-TRIAL OF WRL-105 STRAIN LIVE ATTENUATED INFLUENZA VACCINE COMPARING 4 METHODS OF INTRANASAL VACCINATION
    FREESTONE, DS
    BOWKER, CH
    LETLEY, E
    FERRIS, RD
    WHITE, WG
    BARNES, GM
    JOURNAL OF HYGIENE, 1976, 76 (03) : 459 - 466
  • [43] PREVENTION OF INFLUENZA BY THE INTRANASAL ADMINISTRATION OF COLD-RECOMBINANT, LIVE-ATTENUATED INFLUENZA-VIRUS VACCINE - IMPORTANCE OF INTERFERON-GAMMA PRODUCTION AND LOCAL IGA RESPONSE
    TOMODA, T
    MORITA, H
    KURASHIGE, T
    MAASSAB, HF
    VACCINE, 1995, 13 (02) : 185 - 190
  • [44] Egg protein in the intranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children
    Turner, P.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2015, 45 (02): : 530 - 530
  • [45] Public health impact and return on investment of Belgium's pediatric immunization program
    Carrico, Justin
    Mellott, Claire E.
    Talbird, Sandra E.
    Bento-Abreu, Andre
    Merckx, Barbara
    Vandenhaute, Jessica
    Benchabane, Damia
    Dauby, Nicolas
    Ethgen, Olivier
    Lepage, Philippe
    Luyten, Jeroen
    Raes, Marc
    Simoens, Steven
    Van Ranst, Marc
    Eiden, Amanda
    Nyaku, Mawuli K.
    Bencina, Goran
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [46] A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates
    Song, Haichen
    Nieto, Gloria Ramirez
    Perez, Daniel R.
    JOURNAL OF VIROLOGY, 2007, 81 (17) : 9238 - 9248
  • [47] A MARKOV MODEL EXAMINING THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF MASS VACCINATION USING LIVE ATTENUATED HUMAN ROTAVIRUS VACCINE IN A DEVELOPING ASIAN COUNTRY
    Rose, J.
    Molnar, R. L.
    Watts, B.
    Singer, M. E.
    VALUE IN HEALTH, 2009, 12 (03) : A9 - A9
  • [48] Live-attenuated influenza vaccine effectiveness against hospitalization in children aged 2-6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14-2015/16
    Boddington, Nicki L.
    Mangtani, Punam
    Zhao, Hongxin
    Verlander, Neville Q.
    Ellis, Joanna
    Andrews, Nick
    Pebody, Richard G.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (05) : 897 - 905
  • [49] Quadrivalent Live-Attenuated Influenza Vaccine in Milan preschools: an Italian experience of school-located flu vaccination within the 2022-2023 season
    Roncaglia, Stefania
    Amendola, Antonella
    Baldassarre, Paola
    Barilli, Francesca
    Bianchi, Silvia
    Biuso, Andrea
    Chillemi, Claudia
    Fappani, Clara
    Gasparini, Chiara
    Gori, Maria
    Guida, Gabriella
    Ripoli, Francesca
    Sgambetterra, Laura
    Tanzi, Elisabetta
    Zuccotti, Gian Vincenzo
    ITALIAN JOURNAL OF PEDIATRICS, 2024, 50 (01)
  • [50] Hospitalizations within 14 days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010-2012
    Millman, Alexander J.
    Reynolds, Sue
    Duffy, Jonathan
    Chen, Jufu
    Gargiullo, Paul
    Fry, Alicia M.
    VACCINE, 2017, 35 (04) : 529 - 535